AstraZeneca picks Publicis and WPP as advertising partners
October 27, 2003AstraZeneca will work exclusively with Publicis and WPP agencies in the US following a rationalisation of its advertising partnerships.The review, …
Pension fund urges GSK to act on AIDS
October 27, 2003The world's largest pension fund has urged GlaxoSmithKline to step up its efforts to help combat the AIDS pandemic in …
Long-awaited diabetes NSF launched
October 27, 2003The long awaited diabetes national service framework has been launched with demanding new targets for the improvement of NHS services.By …
Investment banker to be Elan chief executive
October 27, 2003Elan
Kelly Martin, a former senior executive at Merrill Lynch, has been named chief executive of troubled Irish pharmaceutical company Elan.The …
Industry’s legal challenge to ‘arbitrary’ pricing
October 27, 2003European industry body EFPIA is seeking legal action against the Italian Government new reimbursement and pricing policy, which it believes …
Deadlock over access to medicines
October 27, 2003A row over patents on diabetes and asthma drugs has produced a deadlock in talks to improve access to medicines …
Pharmacia chief tipped for Schering role
October 27, 2003Current Pharmacia Chief Executive Fred Hassan has been tipped to take over the top job at Schering-Plough once the Pfizer/Pharmacia …
NHS diabetes czar appointed
October 27, 2003Leading diabetes specialist Dr Sue Roberts has been appointed as the new National Clinical Director for Diabetes, and will oversee …
Roche records $2.8bn loss in 2002
October 27, 2003Roche has recorded a $2.8 billion net loss for 2002 after writing off CHF9 billion costs following its embarrassing exit …
EU regulator submits expansion plans
October 27, 2003Medicines regulator the EMEA has asked the European Union for a subsidy increase of nearly 13% to pay for its …
Bayer denies Lipobay cover-up
October 27, 2003Bayer has refuted allegations that it concealed serious side-effects of its statin Lipobay before it was withdrawn in July 2001.US …
Pfizer picks US research ‘hotspot’ for trials centre
October 27, 2003Pfizer is to build a new $35 million clinical research centre in an R&D 'hotspot' in New Haven, Connecticut.Due to …
Abbott surprised by early Humira approval
October 27, 2003Abbott Laboratories says US approval of its rheumatoid arthritis product Humira has come earlier than expected, and will now increase …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
